| Literature DB >> 31138956 |
Narumi Nagai1, Satomi Yagyu1, Anna Hata1, Shinsuke Nirengi2, Kazuhiko Kotani2,3, Toshio Moritani4, Naoki Sakane2.
Abstract
Maslinic acid, derived from olive fruit, reduces pro-inflammation cytokines, which are involved in muscle fiber atrophy. Therefore, the maslinic acid ingestion may enhance the muscular response to resistance training through anti-inflammatory action. We therefore conducted a parallel, double-blind, randomized, placebo-controlled trial that examined whether a combination of maslinic acid supplementation and resistance training improve mobility functions in community-dwelling elderly persons. Over a 12-week period, 36 participants underwent moderate resistance training and are assigned to the maslinic acid supplementation (n = 17, 60 mg/day) or the placebo (n = 19) group. At baseline and at 12-weeks, we assessed body composition, grip strength, walking speed, leg strength, mobility functions, and knee pain scores. Following the 12-weeks, skeletal muscle mass, segmental muscle mass (right arm, left arm, and trunk) and knee pain score of the right leg were significantly improved in the maslinic acid group, while there was no change or parameters had worsened in the placebo group. Grip strength of the better side significantly increased only in the maslinic acid group. These results suggest that maslinic acid supplementation combined with moderate resistance training may increase upper muscle mass and grip strength, and reduce knee pain, could be effective for preventing mobility-related disability in elderly persons. Clinical trial registration number: UMIN000017207.Entities:
Keywords: geriatrics; knee pain; maslinic acid; muscle mass; resistance training
Year: 2019 PMID: 31138956 PMCID: PMC6529705 DOI: 10.3164/jcbn.18-104
Source DB: PubMed Journal: J Clin Biochem Nutr ISSN: 0912-0009 Impact factor: 3.114
Fig. 1CONSORT Flow diagram. Flowchart of participant recruitment and dropouts before and during the study. F, female participant; M, Male participant.
Baseline characteristics of the study participants†
| Variables | MA group ( | Placebo group ( |
|---|---|---|
| No of women | 11 | 13 |
| Age (years) | 72.7 ± 1.4 | 73.5 ± 2.3 |
| Education (years) | 11.6 ± 2.3 | 11.6 ± 1.9 |
| Height (cm) | 154.9 ± 5.2 | 154.0 ± 7.3 |
| Body mass (kg) | 52.6 ± 8.2 | 55.7 ± 11.0 |
| Body mass index (kg/m2) | 21.9 ± 3.1 | 23.4 ± 3.7 |
| Systolic blood pressure (mmHg) | 140.0 ± 14.0 | 135.1 ± 18.0 |
| Diastolic blood pressure (mmHg) | 76.0 ± 10.0 | 77.5 ± 10.0 |
| Resting heart rate (bpm) | 67.0 ± 11.4 | 72.3 ± 12.7 |
| Enegy intake (MJ/day) | 7.89 ± 2.16 | 8.37 ± 1.97 |
| Protein intake (g/day) | 70.9 ± 20.7 | 77.8 ± 18.8 |
| Duration of habitual exercise (min/week) | 182 ± 140 | 217 ± 166 |
| Duration of sleep (min/day) | 475 ± 75 | 474 ± 41 |
Mean values with their standard deviations. MA, maslinic acid. †Unpaired t test showed no significant differences at baseline between the two groups.
Body mass, body composition, segmental muscle mass and mobility related functions
| MA group ( | Placebo group ( | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | 12 weeks | Baseline | 12 weeks | ||||
| Body mass (kg) | 52.6 ± 8.2 | 52.4 ± 8.5 | 0.43 | 55.7 ± 11.0 | 55.1 ± 10.9 | 0.049 | 0.38 |
| Body mass index (kg/m2) | 21.9 ± 3.1 | 21.8 ± 3.2 | 0.48 | 23.4 ± 3.7 | 23.1 ± 3.7 | 0.056 | 0.37 |
| Body composition | |||||||
| Fat mass (%) | 25.7 ± 6.8 | 24.6 ± 7.3 | 0.011 | 29.0 ± 7.8 | 28.6 ± 8.0 | 0.37 | 0.26 |
| Fat free mass (%) | 71.5 ± 8.0 | 75.4 ± 7.3 | 0.11 | 71.0 ± 7.8 | 74.4 ± 6.8 | 0.33 | 0.066 |
| Skeletal muscle mass (kg) | 20.9 ± 3.4 | 21.1 ± 3.4 | 0.061 | 21.1 ± 4.3 | 21.0 ± 4.4 | 0.25 | 0.032 |
| Segmental muscle mass | |||||||
| Right arm (kg) | 1.89 ± 0.44 | 1.95 ± 0.46 | <0.001 | 1.92 ± 0.52 | 1.91 ± 0.54 | 0.74 | 0.001 |
| Left arm (kg) | 1.86 ± 0.42 | 1.90 ± 0.44 | 0.005 | 1.89 ± 0.53 | 1.86 ± 0.54 | 0.19 | 0.011 |
| Trunk (kg) | 17.05 ± 2.61 | 17.30 ± 2.69 | <0.001 | 17.17 ± 3.33 | 17.09 ± 3.38 | 0.31 | 0.002 |
| Right leg (kg) | 5.75 ± 0.99 | 5.73 ± 1.05 | 0.74 | 5.78 ± 1.26 | 5.73 ± 1.25 | 0.45 | 0.74 |
| Left leg (kg) | 5.74 ± 0.98 | 5.75 ± 1.06 | 0.96 | 5.76 ± 1.24 | 5.76 ± 1.24 | 0.96 | 1.00 |
| Physical performance | |||||||
| Grip strength (better side, kg) | 24.3 ± 7.4 | 25.7 ± 7.2 | 0.025 | 23.2 ± 7.4 | 24.1 ± 7.3 | 0.20 | 0.57 |
| Timed 5-m walk (s) | 2.90 ± 0.26 | 3.04 ± 0.25 | 0.015 | 3.00 ± 0.34 | 3.17 ± 0.37 | 0.003 | 0.66 |
| Stand-up from chair (times/30 s) | 17.4 ± 2.2 | 18.2 ± 3.9 | 0.42 | 18.2 ± 2.9 | 17.5 ± 3.9 | 0.20 | 0.16 |
| Mobility function score (score, 1–5) | 1.2 ± 1.1 | 0.9 ± 0.8 | 0.26 | 0.8 ± 1.0 | 1.0 ± 1.0 | 0.27 | 0.11 |
| Osteoarthritis index (WOMAC) | |||||||
| Total (score) | 129.8 ± 5.3 | 130.4 ± 5.2 | 0.38 | 130.4 ± 6.4 | 130.7 ± 6.2 | 0.83 | 0.78 |
| Knee function (score) | 82.6 ± 2.6 | 82.5 ± 3.6 | 0.59 | 81.9 ± 4.5 | 81.7 ± 4.9 | 0.73 | 0.45 |
| Pain in right knee (score) | 23.6 ± 2.1 | 24.3 ± 1.2 | 0.26 | 24.2 ± 1.6 | 24.2 ± 1.4 | 1.00 | 0.040 |
| Pain in left knee (score) | 23.5 ± 1.8 | 23.6 ± 2.3 | 0.83 | 24.2 ± 1.4 | 24.7 ± 0.6 | 0.14 | 0.56 |
Mean values with their standard deviations. MA, maslinic acid. WOMAC, Western Ontario and McMaster Universities osteoarthritis index. Higher scores represent better situation or less pain. †P value obtained from paired t test to compare changes from baseline assessment (baseline vs 12 weeks) within the MA and the placebo groups. ††P value represents between-group comparison of changes from baseline assessment (baseline vs 12 weeks) in repeated measurement ANOVA assessing group × time interaction.